The debate concerning a possible role of other genes in hereditary GC began only in the last few years, with the spread of MGPT in the research setting and the achievement of some evidence concerning a possible association with GC risk, especially in BRCA2, PALB2, ATM, and other DNA repair gene PV carriers [11,12,21,22]. This evidence concerns the gene BRCA2 and gastric cancer.